A study presented during the February 2024 session of the American Society for Clinical Oncology Plenary Series shows that triplet therapy of belantamab mafodotin (belamaf) plus bortezomib and dexamethasone significantly improves outcomes for patients with relapsed or refractory multiple myeloma (RRMM), with an acceptable safety profile. The trial found that the median progression-free survival (PFS) was 36.6 months with the BVd regimen compared to 13.4 months for the DVd regimen. The overall response rate was also higher in the BVd arm compared to the DVd arm. The study’s findings suggest BVd triplet therapy as a potential new standard of care option for patients with relapsed or refractory multiple myeloma.
Source link
Triplet therapy including belamaf prolongs survival in multiple myeloma
